Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an update.
Shanghai Junshi Biosciences has completed the issuance of its 2026 first tranche of technology innovation bonds, raising RMB1 billion with a 3+2-year term maturing in January 2031 at an interest rate of 2.70%. The successful bond issuance strengthens the company’s funding position to support its innovation-driven operations and future development, while the board has cautioned shareholders and potential investors to exercise care when trading the company’s securities.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong that focuses on biotechnology innovation, including the research, development and commercialization of innovative therapies, serving the healthcare and life sciences markets domestically and abroad.
Average Trading Volume: 2,962,110
Technical Sentiment Signal: Sell
Current Market Cap: HK$37.04B
For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.